- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Interventions
- Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cell, Cyclosporine, Sirolimus, Busulfan, Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection
- Radiation · Drug · Biological + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington
Location Directory
Clinical trials in Seattle, Washington
This page shows live ClinicalTrials.gov search results for Seattle, Washington, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
11419
Shown on this page
12
Current sort
Recently updated
Location scope
Seattle, WA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 805–816 of 11,419 matching trials in Seattle, WA.
Live ClinicalTrials.gov results.
Institutions in Seattle
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 25
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 18 more
- Conditions
- Breast Carcinoma
- Interventions
- IM@Home Program, Medical Device Usage and Evaluation, Questionnaire Administration, Interview
- Behavioral · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Seattle, Washington • Spokane Valley, Washington
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- NVL-330
- Drug
- Lead sponsor
- Nuvalent Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Irvine, California • Sacramento, California • Stanford, California + 13 more
- Conditions
- Acute Otitis Media (AOM)
- Interventions
- Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
- Conditions
- Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Fecal Microbiota Transplantation Capsule, Placebo
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Transthyretin Amyloidosis With Cardiomyopathy
- Interventions
- Nucresiran, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 45
- States / cities
- La Jolla, California • Laguna Hills, California • Stanford, California + 38 more
- Conditions
- ACUTE SINUSITIS, Sinusitis
- Interventions
- Amoxicillin, Amoxi Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
- Conditions
- Breast Cancer
- Interventions
- Positron emission tomography (PET), Trastuzumab, Pertuzumab
- Procedure · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
- Conditions
- Malignant Female Reproductive System Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Unresectable Malignant Female Reproductive System Neoplasm
- Interventions
- Not listed
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
- Interventions
- Sonrotoclax, Zanubrutinib
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 17
- States / cities
- Duarte, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Procedure · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2033
- U.S. locations
- 23
- States / cities
- Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more